Open AccessDevelopment of an UPLC-MS/MS Method for the Quantitative Analysis of Upadacitinib in Beagle Dog Plasma and Pharmacokinetics Study
Author(s) -
Meng-Jie Wang,
Yu-Hang Zhao,
Chenyi Fan,
Ying-Jie Wang,
Xin-Qi Wang,
Xiangjun Qiu,
Ruijie Shen
Publication year - 2021
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s332282
Subject(s) - chromatography , chemistry , pharmacokinetics , formic acid , selected reaction monitoring , therapeutic drug monitoring , high performance liquid chromatography , tandem mass spectrometry , mass spectrometry , pharmacology , medicine
Upadacitinib, a novel selective Janus kinase 1 (JAK1) inhibitor, has been recently approved by the US FDA for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). An ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method for the quantitative analysis of upadacitinib in beagle dog plasma was developed and validated.